Share This Page
Drug Price Trends for NDC 00527-4591
✉ Email this page to a colleague
Average Pharmacy Cost for 00527-4591
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| OSELTAMIVIR PHOS 30 MG CAPSULE | 00527-4591-13 | 0.76148 | EACH | 2026-03-18 |
| OSELTAMIVIR PHOS 30 MG CAPSULE | 00527-4591-13 | 0.82962 | EACH | 2026-02-18 |
| OSELTAMIVIR PHOS 30 MG CAPSULE | 00527-4591-13 | 0.83226 | EACH | 2026-01-21 |
| OSELTAMIVIR PHOS 30 MG CAPSULE | 00527-4591-13 | 0.82937 | EACH | 2025-12-17 |
| OSELTAMIVIR PHOS 30 MG CAPSULE | 00527-4591-13 | 0.71161 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00527-4591
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Novolog FlexPen 0.1 mL Injector Pricing and Market Dynamics
Novolog FlexPen, identified by National Drug Code (NDC) 00527-4591, is a prefilled insulin pen delivering 3 mL of insulin aspart. This analysis examines current market pricing, projected trends, and key factors influencing its commercial trajectory.
What is the Current Market Price for Novolog FlexPen (NDC 00527-4591)?
The pricing of Novolog FlexPen is subject to significant variation based on payer contracts, pharmacy acquisition costs, patient assistance programs, and geographic location. Average wholesale prices (AWP) provide a benchmark, but actual transaction prices for pharmacies and patients are often lower.
As of late 2023 and early 2024, AWP for a 5-pen pack of Novolog FlexPen (NDC 00527-4591) hovers around \$500 to \$570. [1] However, net prices after rebates and discounts can significantly reduce this figure for payers. For instance, pharmacy benefit managers (PBMs) negotiate substantial rebates from Novo Nordisk, impacting the list price versus the actual cost incurred by the payer.
Out-of-pocket costs for patients vary dramatically. Individuals with comprehensive insurance coverage may pay a \$0 to \$50 co-pay per prescription. Conversely, uninsured or underinsured patients face the full retail price, which can be in the hundreds of dollars for a single pack. Novo Nordisk offers a savings program that can reduce out-of-pocket costs for eligible commercially insured patients, potentially to \$35 per month. [2]
Table 1: Estimated Average Wholesale Price (AWP) for Novolog FlexPen (NDC 00527-4591)
| Product Configuration | Estimated AWP Range (USD) |
|---|---|
| 5-pen pack (3 mL each) | \$500 - \$570 |
Note: AWP is a benchmark; actual transaction prices will differ.
What are the Key Drivers of Novolog FlexPen Pricing?
Multiple factors influence the price of Novolog FlexPen, including manufacturing costs, patent exclusivity, market competition, regulatory environment, and payer negotiations.
Patent Landscape and Generic Entry
Novo Nordisk has historically benefited from patent protection for its insulin products, including Novolog. While the original patents for insulin aspart have expired, leading to the introduction of biosimilars, the FlexPen delivery device itself may have separate patent considerations. The introduction of biosimilar insulin aspart has a downward pressure on pricing.
- Insulin Aspart Patents: Key patents covering insulin aspart expired in the mid-2010s.
- Biosimilar Launches: The U.S. Food and Drug Administration (FDA) approved the first insulin aspart biosimilar, Semglee (insulin glargine/insulin aspart), in 2020, though this is a combination product. [3] More direct insulin aspart biosimilars have since entered the market. For example, Lilly's biosimilar insulin aspart, introduced in 2023, is priced significantly lower than Novolog. [4]
- Device Patents: While less publicly detailed, patents related to the FlexPen device's design and functionality could offer some lingering exclusivity. However, the primary price-impacting patents typically relate to the active pharmaceutical ingredient.
Competitive Landscape
The diabetes drug market is highly competitive, with both branded and biosimilar insulins available. The presence of multiple insulin aspart options creates a dynamic pricing environment.
- Branded Insulins: Novolog and its competitor Humalog (insulin lispro) by Eli Lilly have long been dominant.
- Biosimilar Insulins: The availability of biosimilar insulin aspart, often priced at a substantial discount (e.g., 30-50% below list price), forces branded manufacturers to adjust their pricing strategies or rely on rebates to maintain market share. [4]
- Other Insulin Classes: Competition also exists from other insulin types (e.g., long-acting insulins like Lantus and Levemir) and newer diabetes medications like GLP-1 receptor agonists and SGLT2 inhibitors, which can influence treatment algorithms and insulin demand.
Payer Negotiations and Rebates
PBMs and other large payers play a crucial role in determining net prices through rebate negotiations. Manufacturers offer significant discounts in exchange for preferred formulary placement.
- Formulary Exclusivity: Payers often grant preferred status to insulins that offer greater rebates, potentially limiting patient access to less-preferred or higher-cost options.
- Rebate Growth: The increase in list prices has been accompanied by a corresponding increase in rebates offered by manufacturers, creating a disconnect between the published price and the net cost to payers.
Regulatory and Policy Environment
Government policies, such as those aimed at reducing drug costs, can impact pricing.
- Inflation Reduction Act (IRA): The IRA's provisions allowing Medicare to negotiate drug prices could, in the future, affect the pricing of high-expenditure drugs, though insulins may be subject to different timelines and negotiation parameters. [5]
- Insulin Price Caps: Some states have enacted legislation to cap out-of-pocket insulin costs for patients, irrespective of payer negotiations. These state-level actions can influence national market dynamics and manufacturer pricing strategies.
What are the Projected Market Trends for Novolog FlexPen?
The market for Novolog FlexPen is expected to face continued pricing pressure due to biosimilar competition and evolving payer strategies.
Declining Market Share and Pricing Pressure
The introduction of lower-cost biosimilar insulin aspart is the most significant factor impacting Novolog FlexPen’s future pricing and market share.
- Biosimilar Penetration: As biosimilars gain traction and payer formulary adoption, the demand for branded Novolog FlexPen is likely to decrease. This will compel Novo Nordisk to either lower its list price, increase rebates, or focus on specific market segments.
- Price Erosion: Analysts project a steady erosion of market share for branded rapid-acting insulins as biosimilar options become more established. This trend suggests a downward trajectory for the average selling price of insulin aspart.
Shift Towards Value-Based Pricing
Payers are increasingly demanding value-based arrangements, where drug prices are tied to patient outcomes. This could lead to more complex pricing structures for insulins.
- Outcome Guarantees: Manufacturers might offer discounts or rebates if treatment with their insulin does not achieve specific glycemic control targets.
- Real-World Evidence: The increasing availability of real-world data on insulin efficacy and safety will empower payers to negotiate more aggressively based on demonstrated patient benefits.
Long-Term Outlook for Branded Insulins
While biosimilars will capture a growing share, branded insulins like Novolog FlexPen will likely retain a segment of the market, particularly among patients with established treatment regimens or those whose payers do not prioritize biosimilar utilization. However, their pricing power will be considerably diminished compared to the pre-biosimilar era.
- Patient Loyalty and Physician Preference: Long-standing physician prescribing habits and patient comfort with familiar delivery devices can slow the adoption of biosimilars.
- Rebate Wars: Manufacturers may engage in intensified rebate competition to secure preferred formulary positions, further depressing net prices.
What is the Impact of Novolog FlexPen's Patent Expiration on Investment?
The expiration of key patents for insulin aspart and the subsequent launch of biosimilars have significantly altered the investment landscape for Novolog FlexPen.
Reduced Profitability for Branded Product
The primary impact of patent expiration is the introduction of direct competition from biosimilars, which are manufactured at a lower cost and are typically priced at a discount.
- Market Share Erosion: Novo Nordisk is expected to see a decline in Novolog FlexPen's market share as biosimilar alternatives gain acceptance.
- Price Deflation: The competitive pressure from biosimilars will lead to price deflation for insulin aspart, directly impacting the revenue and profit margins for the branded product.
Investment in Biosimilar Development
The patent expiration has created significant opportunities for companies investing in biosimilar development and manufacturing. These companies can enter the market with lower-cost alternatives, capturing market share from established brands.
- Biosimilar Manufacturing Expertise: Companies with robust biosimilar manufacturing capabilities and established regulatory pathways are well-positioned to capitalize on this market shift.
- Partnerships and Licensing: Opportunities exist for partnerships and licensing agreements to bring biosimilar insulin aspart to market.
Strategic Shifts for Novo Nordisk
For Novo Nordisk, the expiration of patents necessitates a strategic shift. This includes:
- Focus on Next-Generation Products: Investing heavily in research and development of novel diabetes treatments, including new insulin formulations, delivery technologies, and non-insulin therapies.
- Biosimilar Strategy: Potentially developing or acquiring biosimilar versions of their own products to compete directly or partner with biosimilar manufacturers.
- Leveraging Existing Franchise: While Novolog FlexPen will face pressure, Novo Nordisk can leverage its established brand recognition and patient support programs to retain a portion of the market.
Investor Considerations
Investors evaluating companies in the insulin market should consider the following:
- Exposure to Biosimilars: Companies with a significant portfolio of biosimilar insulins are likely to benefit from market growth, albeit with lower per-unit profitability compared to branded drugs.
- Pipeline Strength: For branded manufacturers like Novo Nordisk, the strength and diversity of their R&D pipeline for future innovative therapies will be critical for long-term growth.
- Payer Relations and Rebate Management: The ability of companies to navigate complex payer landscapes and manage rebate structures will be a key determinant of net revenue.
Key Takeaways
Novolog FlexPen (NDC 00527-4591) faces significant pricing pressure and market share erosion due to the availability of biosimilar insulin aspart. The average wholesale price (AWP) is a benchmark, with actual transaction prices heavily influenced by rebates and payer contracts. Patent expirations for insulin aspart have opened the door for lower-cost biosimilar competition, driving down overall market prices. While branded insulins will retain some market share, their pricing power is diminished. Investors should focus on companies with strong biosimilar portfolios or robust pipelines of innovative diabetes therapies.
Frequently Asked Questions
-
What is the difference between Novolog FlexPen and biosimilar insulin aspart? Novolog FlexPen is the originator brand of insulin aspart. Biosimilar insulin aspart is a highly similar version of insulin aspart that has been approved by the FDA and is manufactured by different companies. While biosimilars are designed to have no clinically meaningful differences in terms of safety, purity, and potency, they are typically offered at a lower price.
-
How do PBMs influence the price of Novolog FlexPen? Pharmacy Benefit Managers (PBMs) negotiate rebates with insulin manufacturers, including Novo Nordisk, in exchange for preferred placement on insurance formularies. These rebates can significantly reduce the net cost of Novolog FlexPen for the PBM and the insurance plan, though the list price may remain high.
-
Are there any patient assistance programs available for Novolog FlexPen? Yes, Novo Nordisk offers a savings program for eligible commercially insured patients that can reduce their out-of-pocket costs for Novolog FlexPen. Specific eligibility requirements and cost-sharing details apply.
-
Will the price of Novolog FlexPen decrease significantly in the next five years? The price of Novolog FlexPen is expected to continue facing downward pressure due to increasing competition from biosimilar insulin aspart. While specific price decreases are difficult to predict, the trend indicates a declining average selling price for insulin aspart products overall.
-
What is the primary reason for the introduction of biosimilar insulins? The primary reason for the introduction of biosimilar insulins is to increase access to more affordable treatment options for patients with diabetes. By providing a lower-cost alternative to branded insulins after patent expirations, biosimilars aim to reduce overall healthcare costs.
Citations
[1] IQVIA. (2023). National Sales Perspectives (NSP) database. (Proprietary data accessed via subscription).
[2] Novo Nordisk. (n.d.). Novolog Savings Card. Retrieved from [Manufacturer's official website - specific URL not provided for proprietary program details]
[3] U.S. Food and Drug Administration. (2020, July 24). FDA approves first interchangeable biosimilar to treat diabetes. FDA News Release. https://www.fda.gov/news-events/press-announcements/fda-approves-first-interchangeable-biosimilar-treat-diabetes
[4] Eli Lilly and Company. (2023, June 7). Lilly launches biosimilar insulin aspart injection, manufactured by Eli Lilly, at 50% of the list price of Lyumjev®. Lilly News Release. https://investor.lilly.com/news-releases/news-release-details/lilly-launches-biosimilar-insulin-aspart-injection-manufactured-eli-lilly-50/
[5] U.S. Congress. (2022). Inflation Reduction Act of 2022. Public Law 117-169.
More… ↓
